Aurora Cannabis posts $67.6M Q1 revenue with 17% growth in international medical cannabis sales

Aurora Cannabis reported $67.6 million in net revenue for Q1 2027, driven by a 17% year-over-year increase in international medical cannabis sales, particularly in Germany. Despite a 25% decline in Canadian medical cannabis revenue due to federal reimbursement cuts, the company strengthened its position with the acquisition of Safari Flower Company, which received a three-year EU-GMP certification to boost international supply capacity. Aurora expects sequential revenue and adjusted EBITDA growth in Q2, focusing on expanding its global medical cannabis market presence while winding down its consumer cannabis business in Canada.